Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Profit After Tax (2020 - 2025)

Cytek Biosciences' Profit After Tax history spans 6 years, with the latest figure at -$44.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 557.08% year-over-year to -$44.1 million; the TTM value through Dec 2025 reached -$66.5 million, down 1005.48%, while the annual FY2025 figure was -$66.5 million, 1005.3% down from the prior year.
  • Profit After Tax reached -$44.1 million in Q4 2025 per CTKB's latest filing, down from -$5.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $9.6 million in Q4 2024 to a low of -$44.1 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$4.0 million, with a median of -$1.7 million recorded in 2021.
  • The largest YoY upside for Profit After Tax was 419.14% in 2022 against a maximum downside of 2215.69% in 2022.
  • A 5-year view of Profit After Tax shows it stood at -$1.2 million in 2021, then soared by 419.14% to $3.7 million in 2022, then skyrocketed by 48.01% to $5.5 million in 2023, then soared by 75.23% to $9.6 million in 2024, then plummeted by 557.08% to -$44.1 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Profit After Tax are -$44.1 million (Q4 2025), -$5.5 million (Q3 2025), and -$5.6 million (Q2 2025).